Epizyme, Inc.

Michael Thomenius

Scott Ribich

Michael John Munchhof

Kenneth William Duncan

John Emmerson Campbell

Lawrence Alan Reiter

John W Lampe

Darren Martin Harvey

Megan Alene Cloonan Foley

Jennifer Anne Totman

Alexandra Rose Grassian

Compounds of Formula I: (I) and the pharmaceutically acceptable salts and solvates thereof, wherein R, R, G1, G2, Q, Q, Q, and (II) are defined as set forth in the specification, as are uses of compounds of Formula I to treat a disease, disorder, or condition such as cancer in a subject.

Substituted indoles and methods of use thereof

The present disclosure provides methods and pharmaceutical compositions for treating or slowing the progression of cancer, i.e., pancreatic cancer or esophageal cancer, by administering to a human subject in need thereof a therapeutically effective amount of an inhibitor of the histone methyltransferase, SETD2.

Methods of treating cancer by inhibiting SETD2

The disclosure provides a method for treating cancer in a subject in need thereof comprising administering to the subject: (a) a therapeutically effective amount of an EZH2 inhibitor and (b) a therapeutically effective amount of an immune checkpoint inhibitor. In certain embodiments of the methods of the disclosure, the EZH2 inhibitor is tazemetostat.

Use of EZH2 inhibitors for treating cancer

The present disclosure relates to compositions comprising inhibitors of human histone methyltransferase EZH2 and one or more other therapeutic agents, for example, modulators of CD40 pathway activity, such as CD40 agonists, and methods of combination therapy for administering to subjects in need thereof for the treatment of cancer.

EZH2 inhibitors for treating cancer

Growing community of inventors

Rockland, MA, United States of America

Michael Thomenius